J. Lipid Res. Did you know there is a large type edition? Click here.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1194/jlr.R300016-JLR200 on December 1, 2003

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
R300016-JLR200v1
45/2/205    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sun, G. Y.
Right arrow Articles by Simonyi, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sun, G. Y.
Right arrow Articles by Simonyi, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Lipid Research, Vol. 45, 205-213, February 2004
Copyright © 2004 by American Society for Biochemistry and Molecular Biology

Thematic Review

Phospholipase A2 in the central nervous system

: implications for neurodegenerative diseases

Grace Y. Sun2, Jianfeng Xu1, Michael D. Jensen and Agnes Simonyi

Department of Biochemistry, University of Missouri, Columbia, MO 65211

Published, JLR Papers in Press, December 1, 2003. DOI 10.1194/jlr.R300016-JLR200

1 Present address of J. Xu: Division of Experimental Medicine, Harvard Institute of Medicine and Beth Israel Deaconess Medical Center, Boston, MA 02115. Back

2 To whom correspondence should be addressed. e-mail: sung{at}health.missouri.edu


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 PLA2
 PLA2 IN ASTROCYTES
 PLA2 IN MICROGLIAL CELLS
 PLA2 IN NEURONS
 PLA2 IN NEUROBLASTOMA CELLS
 PLA2 IN NEURODEGENERATIVE...
 SUMMARY
 REFERENCES
 
Phospholipase A2 (PLA2) belongs to a family of enzymes that catalyze the cleavage of fatty acids from the sn-2 position of phospholipids. There are more than 19 different isoforms of PLA2 in the mammalian system, but recent studies have focused on three major groups, namely, the group IV cytosolic PLA2, the group II secretory PLA2 (sPLA2), and the group VI Ca2+-independent PLA2. These PLA2s are involved in a complex network of signaling pathways that link receptor agonists, oxidative agents, and proinflammatory cytokines to the release of arachidonic acid (AA) and the synthesis of eicosanoids. PLA2s acting on membrane phospholipids have been implicated in intracellular membrane trafficking, differentiation, proliferation, and apoptotic processes. All major groups of PLA2 are present in the central nervous system (CNS). Therefore, this review is focused on PLA2 and AA release in neural cells, especially in astrocytes and neurons. In addition, because many neurodegenerative diseases are associated with increased oxidative and inflammatory responses, an attempt was made to include studies on PLA2 in cerebral ischemia, Alzheimer's disease, and neuronal injury due to excitotoxic agents.

Information from these studies has provided clear evidence for the important role of PLA2 in regulating physiological and pathological functions in the CNS.

Abbreviations: AA, arachidonic acid; AD, Alzheimer's disease; COX, cyclooxygenase; cPLA2, cytosolic PLA2; DHA, docosahexaenoic acid; ERK, extracellular signal-regulated protein kinase; FFA, free fatty acid; IFN{gamma}, interferon gamma; IL-1ß, interleukin-1ß; iPLA2, Ca2+-independent PLA2; KA, kainic acid; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; MCA, middle cerebral artery; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NMDA, N-methyl-D-aspartic acid; PE, phosphatidylethanolamine; PEpl, ethanolamine plasmalogen; PGE2, prostaglandin E2; PLA2, phospholipase A2; ROS, reactive oxygen species; sPLA2, secretory PLA2; TNF{alpha}, tumor necrosis factor alpha

Supplementary key words astrocytes • neurons • neurodegeneration • Alzheimer's disease • cerebral ischemia


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
PLA2
 PLA2 IN ASTROCYTES
 PLA2 IN MICROGLIAL CELLS
 PLA2 IN NEURONS
 PLA2 IN NEUROBLASTOMA CELLS
 PLA2 IN NEURODEGENERATIVE...
 SUMMARY
 REFERENCES
 
Bazan (1) recognized the important role of arachidonic acid (AA) in the central nervous system (CNS) in the '70s when he observed the rapid and transient release of this fatty acid in the brain due to seizure and cerebral ischemia. The "Bazan effect" has since stimulated over 30 years of investigations attempting to unravel mechanisms regulating AA release from membrane phospholipids in the CNS.

Phospholipids in CNS membranes are enriched in polyunsaturated fatty acids (PUFAs) (2). Metabolism of PUFA is stringently controlled by phospholipase A2 (PLA2) and acyltransferases—known as the "deacylation-reacylation cycle" (3–5). Under normal conditions, free fatty acids (FFAs) released by PLA2 are rapidly taken up by membrane phospholipids through an energy-dependent process involving CoA and ATP (6). To date, limited information is available on the structure and functions of acyltransferases. However, recent advances in molecular biological techniques have aided in the identification of many genes encoding different groups of PLA2 and have provided new information on the properties and functions of these molecules.

PLA2 (EC3.1.1.4.) belongs to a family of enzymes that catalyze the cleavage of fatty acids from the sn-2 position of phospholipids. These enzymes are not only important for maintenance of cell membrane phospholipids; they also play a key role in regulating the release of AA, a precursor for synthesis of eicosanoids. In the mammalian system, more than 19 different isoforms of PLA2 have been identified, and different PLA2s have been shown to participate in physiological events related to cell injury, inflammation, and apoptosis (7, 8). Recent studies have focused on three major groups of PLA2: the group IV calcium-dependent cytosolic PLA2 (cPLA2), the group II secretory PLA2 (sPLA2), and the group VI Ca2+-independent PLA2 (iPLA2) (9). During the past decade, excellent reviews describing the structure and properties of these PLA2s in non-neural systems have appeared (7–11). In addition, two reviews focusing on PLA2 in brain tissue have also been published (12, 13). The present review is devoted to PLA2 in neural cells in the CNS, especially the signaling pathways regulating different PLA2s in neurons and astrocytes (see Fig. 1) . Because PLA2s have been implicated in the pathology of a number of neurodegenerative diseases, an attempt was also made to include recent studies describing the different groups of PLA2s in cerebral ischemia, Alzheimer's disease (AD), and neuronal injury due to excitotoxic agents. To facilitate updated information, a website linking data concerning PLA2s in different neural cells and their involvement in neurodegenerative diseases has been created: http://www.pla2.com. The authors plan to update the information in this site periodically.



View larger version (38K):
[in this window]
[in a new window]
  		Fig. 1. A scheme representing different PLA2 pathways in astrocytes and neurons.

 

   PLA2
TOP
 ABSTRACT
 INTRODUCTION
 PLA2
PLA2 IN ASTROCYTES
 PLA2 IN MICROGLIAL CELLS
 PLA2 IN NEURONS
 PLA2 IN NEUROBLASTOMA CELLS
 PLA2 IN NEURODEGENERATIVE...
 SUMMARY
 REFERENCES
 
cPLA2
cPLA2 belongs to the group IV PLA2s. Although three isoforms, i.e., cPLA2{alpha}, -ß, and -{gamma}, have been identified, the 85 kDa cPLA2{alpha} has been studied most extensively. This protein is comprised of a C2 domain and multiple phosphorylation sites, including two consensus sites (S505 and S727) for phosphorylation by mitogen-activated protein kinases (MAPKs) (12) and an S515 site for Ca2+/calmodulin (9). The C2 domain confers a Ca2+-dependent translocation mechanism for this cPLA2 (14, 15). Recent studies have provided evidence for translocation of cPLA2 from the cytosol to nuclear membranes (16). Translocation of cPLA2 has also been shown to participate in intracellular membrane trafficking processes, such as those governing the Golgi and endocytic pathways (17). PLA2{alpha} seems to prefer hydrolysis of AA from phosphatidylcholine (9). In macrophages, as well as in other cell systems, agents including G protein-coupled receptor agonists, calcium ionophores, phorbol esters, and zymogens can activate cPLA2, resulting in AA release (12). Through its linkage to receptor-mediated signaling pathways, cPLA2 is an important PLA2 for rapid AA release in cells and for modulating a number of intracellular processes.

sPLA2
The sPLA2 family consists of multiple groups (I, II, III, V, X, and XII) of enzymes characterized by a conserved Ca2+ binding loop and a conserved histidine residue in the catalytic domain (9). The group II sPLA2s, including IIA, IIC, IID, IIE, and IIF isoforms, are low-molecular-weight proteins (~14 kDa) with secretory sequences. Genes for many of the group II sPLA2 isoforms are clustered in chromosome 1 (18). These enzymes do not have strict fatty acid specificity and tend to act on anionic phospholipids in the presence of high concentrations of Ca2+ (9). Of the group II sPLA2s, the IIA enzyme has been studied extensively because of its involvement in inflammatory processes in the peripheral systems (8, 11). In the CNS, group IIA sPLA2 mRNA is expressed in cultured astrocytes and can be induced in response to proinflammatory cytokines [tumor necrosis factor alpha (TNF{alpha}), interleukin-1ß (IL-1ß), and interferon gamma (IFN{gamma})] (19–22). Upregulation of group IIA sPLA2 mRNA expression was observed in brain as a result of global cerebral ischemia (23).

iPLA2
The iPLA2 family is comprised of group VIA and VIB. Group VIA enzyme has at least five splice variants, all with ankyrin repeats, whereas group VIB iPLA2 lacks ankyrin repeats but consists of a signal motif for peroxisome localization (9). Fractionation of bovine brain cytosol by column chromatography resulted in two fractions, a 110 kDa iPLA2 fraction, which prefers hydrolysis of diacyl-glycero-3-phosphoethanolamine, and a 39 kDa iPLA2 fraction, which selectively acts on 1-alkenyl-2-acyl-glycero-3-phosphoethanolamine (ethanolamine plasmalogen, PEpl) (13). Although iPLA2s are generally regarded as housekeeping enzymes for the maintenance of membrane phospholipids, recent studies have revealed novel functional roles for this group of enzymes, i.e., regulation of vascular smooth muscle contraction (24) and apoptotic processes (25). A study by Yang et al. (26) indicated that >70% of PLA2 activity in normal rat brain could be attributed to iPLA2.


   PLA2 IN ASTROCYTES
TOP
 ABSTRACT
 INTRODUCTION
 PLA2
 PLA2 IN ASTROCYTES
PLA2 IN MICROGLIAL CELLS
 PLA2 IN NEURONS
 PLA2 IN NEUROBLASTOMA CELLS
 PLA2 IN NEURODEGENERATIVE...
 SUMMARY
 REFERENCES
 
Astrocytes are the major cell type in the CNS and play multiple functional roles in providing nutrient support to neurons, modulating Ca2+ homeostasis, and regulating neurotransmission, as well as mediating host defense functions. Astrocytes have been shown to contain all major groups of PLA2 (27). Therefore, these cells have been used to study the roles of different groups of PLA2 in normal physiological and pathological functions.

Response to receptor agonists
Although many G protein-coupled receptors are expressed in astrocytes, there is considerable interest in the P2Y nucleotide receptors in these cells. One reason for this interest is that in the brain, ATP is stored at high concentrations in synaptic vesicles and is coreleased with neurotransmitters during neuronal excitation (28). Therefore, P2Y receptors in astrocytes may constitute an important mechanism for mediating communication between neurons and glial cells. Activation of P2Y receptors by extracellular nucleotides such as ATP/UTP has been shown to cause an increase in intracellular Ca2+ concentrations ([Ca2+]i) as well as activation of a number of signaling pathways (29). In astrocytes, activation of P2Y receptors is implicated in reactive gliosis, a pathological condition associated with a number of neurodegenerative diseases (30–32). Several studies have demonstrated the ability of ATP/UTP to stimulate AA release in astrocytes (33–36). A study by Xu et al. (36) further demonstrated the role of the extracellular signal-regulated protein kinase (ERK) and protein kinase C (PKC) pathways for enhancing cPLA2 phosphorylation and stimulating AA release in murine astrocytes. ATP, acting on the P2Y2 receptors in astrocytes, could also mediate the release of docosahexaenoic acid (DHA) (37). However, ATP-mediated release of DHA was shown to involve iPLA2 instead of cPLA2 (37). These results indicate the ability of ATP to stimulate multiple pathways that lead to activation of different PLA2 isoforms.

The activation of endothelin receptor, another G protein-coupled receptor, was shown to cause AA release in astrocytes (38) and in smooth muscle cells (39, 40). The study with smooth muscle cells further demonstrated the involvement of PKC{alpha} and p38 MAP kinase in endothelin-1-mediated AA release (39). Many G protein-coupled receptors are linked to phospholipase C and the release of inositol trisphosphates and diacylglycerols, which are second messengers for Ca2+ mobilization and activation of PKC, respectively. Increases in both [Ca2+]i and PKC are important factors in the translocation and phosphorylation of cPLA2. However, studies in NIH3T3 cells stably expressed with the serotonin 5HT2A receptor indicated that instead of the phospholipase C pathway, 5HT-stimulated PLA2 and AA release involved in both the Gi/o-associated G-mediated ERK1/2 and the G12/13-coupled, Rho-mediated p38 MAP kinase pathways (41, 42). These results illustrate the complexity of different intracellular signaling pathways in the regulation of cPLA2.

Response to oxidative agents
Reactive oxygen species (ROS) are produced in biological systems through both enzymatic and nonenzymatic mechanisms. Excessive generation of ROS in the CNS has been implicated in neuronal damage resulting from cerebral ischemia and in AD. Oxidant compounds such as H2O2 have been shown to cause perturbation of cell membrane integrity and alteration of mitochondrial function, resulting in an increase in [Ca2+]i (43, 44). In fact, H2O2 is a naturally occurring oxidant produced by a number of intracellular reactions, and excessive production of this compound is associated with signaling pathways (45) responsible for activating PKC (46), tyrosine kinase (47), and MAPK (45, 48). In astrocytes, H2O2 can alter phospholipid-hydrolyzing enzymes, including phospholipase D (49) and PLA2 (50). A study in murine astrocytes further indicated the involvement of cPLA2 and iPLA2 in AA release induced by H2O2 (51). On the other hand, a study in mesangial cells that were transfected with cPLA2 and/or sPLA2 demonstrated the involvement of cPLA2 and sPLA2 in H2O2-induced AA release (52).

Response to inflammatory agents
Astrocytes can readily respond to proinflammatory agents and lipopolysaccharides (LPS), causing the induction of a number of genes through activation of the nuclear factor {kappa}B pathway. In primary rat astrocytes, cytokines (TNF{alpha}, IL-1ß, and IFN{gamma}) stimulated the increase in prostaglandin E2 (PGE2) production, which was preceded by an increase in cyclooxygenase-2 (COX-2) and sPLA2 mRNA but not COX-1 and cPLA2 mRNA (22). In another study in rat astrocytes, LPS also increased expression of sPLA2 mRNA but not cPLA2 mRNA (27). Although cytokines did not increase cPLA2 mRNA levels, an increase in cPLA2 phosphorylation was observed (22). The study by Xu et al. (22) further indicated the role of sPLA2 in cytokine-induced production of PGE2. Because C57Bl/6 mice lack the group IIA sPLA2 gene due to a frame shift mutation (53), astrocytes isolated from these mice were less responsive to cytokines in the production of PGE2 than were astrocytes from rat brain (22). On the other hand, a study with lung fibroblasts isolated from cPLA2-deficient mice also showed less PGE2 production as compared with fibroblasts from the wild-type mice, suggesting an important role for cPLA2 in the PGE2 pathway (54). Taken together, these results suggest the involvement of both sPLA2 and cPLA2 in cytokine-mediated PGE2 production.

Cytokines such as IL-1 were shown to enhance ATP-mediated stimulation of PLA2 and AA release in astrocytes (35). A study by Xu et al. (22) showed that exposure of rat astrocytes to proinflammatory cytokines (TNF{alpha}, IL-1ß, and IFN{gamma}) for 16 h followed with cPLA2 agonists (ATP and PMA) for 30 min resulted in 70-fold higher production of PGE2 as compared with astrocytes stimulated with ATP and PMA without prior cytokine exposure. Results from the above studies suggest that in pathological conditions associated with an increase in inflammation, a sustained increase in proinflammatory cytokines in the brain may enhance the response of G protein-coupled receptors to produce higher levels of eicosanoids. In a recent study in our laboratory, exposure of murine astrocytes to 1L-1ß for 12 h resulted in an increase in COX-2 and cPLA2 immunoreactivity (G. Y. Sun et al., unpublished observations). Confocal microscopic examination indicated that COX-2 and cPLA2 are localized in the perinuclear area (Fig. 2) . In a recent report by Pardue, Rapoport, and Bosetti (55), colocalization of cPLA2 and COX-2 were also observed in the cerebellum of Rhesus monkey brain (55).



View larger version (18K):
[in this window]
[in a new window]
  		Fig. 2. Confocal microscopy showing localization of cytosolic PLA2 (cPLA2) and cyclooxygenase-2 (COX-2) in the perinuclear area of primary murine astrocytes following treatment with interleukin-1ß (IL-1ß) (10 ng/ml) for 12 h. Astrocytes were plated on coverslips coated with poly-D-lysine and grown to 50% confluence. Cells were treated with IL-1ß and were washed with Balch Buffer II (BBII) containing 25 mM HEPES, 75 mM potassium acetate, and 5 mM EGTA. Immediately after treatment, cells were fixed with 2% paraformaldehyde in phosphate-buffered saline (pH 7.2) at 25°C for 30 min. Cells were permeabilized and blocked by incubation for 30 min at 25°C with 0.1% (w/v) saponin and 10% (v/v) normal donkey serum diluted in BBII. Cells were incubated with primary antibodies (1:50 rabbit polyclonal anti-cPLA2 IgG or 1:100 goat polyclonal anti-rat COX-2 IgG) diluted in BBII. Incubation with secondary antibodies (1:200 Cy3-conjugated donkey anti-rabbit IgG or 1:200 Cy5-conjugated donkey anti-goat IgG) was carried out at 25°C for 4 h. After three washes with BBII, the coverslips were rinsed with distilled water and mounted on glass slides with Mowilol. The stained cells were viewed with a confocal microscope (Bio-Rad Lasershop 2000).

 
In addition to IL-1ß, other cytokines, such as TNF{alpha}, can also activate COX-2 and stimulate signaling pathways leading to cPLA2 phosphorylation and AA release (56). As shown in the study with human astrocytoma cells (1321N1), TNF{alpha}-stimulated phosphorylation of cPLA2 involved the c-Jun and p38 MAP kinase pathways but not the ERK pathway (56). In addition to group IIA sPLA2, group V sPLA2 was also present in astrocytes, and TNF{alpha} stimulated both types of sPLA2, albeit through different time courses and different pathways (57). These studies demonstrate that different cytokines can activate different isoforms of sPLA2 in astrocytes.


   PLA2 IN MICROGLIAL CELLS
TOP
 ABSTRACT
 INTRODUCTION
 PLA2
 PLA2 IN ASTROCYTES
 PLA2 IN MICROGLIAL CELLS
PLA2 IN NEURONS
 PLA2 IN NEUROBLASTOMA CELLS
 PLA2 IN NEURODEGENERATIVE...
 SUMMARY
 REFERENCES
 
In addition to astrocytes, little is known about PLA2 in other types of glial cells, such as the microglial cells and the oligodendroglial cells. This is due in part to difficulties in isolating sufficient quantities of these cells for biochemical analysis. Microglial cells are immune-active cells and exhibit many properties similar to those of macrophages and astrocytes (58). Therefore, there is substantial interest in the role of PLA2 in the inflammatory responses in these cells. In N9 microglial cells, PLA2 inhibitors could inhibit LPS-induced TNF{alpha} release, suggesting an involvement of PLA2 in the cytokine pathway (59). Although the murine-derived BV-2 microglial cells lack the group IIA sPLA2, they contain high levels of cPLA2 (G. Y. Sun, unpublished observations). In BV-2 cells, AA release stimulated by IFN{gamma} and PMA was PKC and ERK dependent, suggesting the involvement of cPLA2 in mediating the AA release in these cells (G. Y. Sun, unpublished observations). In human microglial cells, LPS was capable of inducing COX-2 mRNA expression and PGE2 production (60). These results suggest that PLA2 may also play a role in mediating the inflammatory cascade in microglial cells.


   PLA2 IN NEURONS
TOP
 ABSTRACT
 INTRODUCTION
 PLA2
 PLA2 IN ASTROCYTES
 PLA2 IN MICROGLIAL CELLS
 PLA2 IN NEURONS
PLA2 IN NEUROBLASTOMA CELLS
 PLA2 IN NEURODEGENERATIVE...
 SUMMARY
 REFERENCES
 
AA is regarded as a neuromodulator in the CNS, and PLA2 is thought to have a role in neuronal plasticity (61). Neuronal excitation resulting from depolarization with high concentrations of potassium (62) and stimulation with excitatory neurotransmitter agonists such as {alpha}-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) (63), N-methyl-D-aspartic acid (NMDA) (64), and glutamate (65), as well as muscarinic cholinergic agonists (66), can stimulate AA release in neurons. Furthermore, oxidant compounds such as H2O2 could further enhance AA release stimulated by a number of neurotransmitter agonists (67). Although there is evidence for the involvement of Ca2+ and cPLA2 in the AA release from neurons, the signaling pathways leading to cPLA2 activation remain unclear.

Studies in vivo have demonstrated cPLA2 mRNA expression in hippocampal neurons (68). Infusion of NMDA into the hippocampus resulted in the activation of cPLA2 and COX-2 expression and the production of PGE2 and PGF2{alpha} (69). Upregulation of cPLA2 expression was also shown in injured cervical neurons and dorsal root ganglia (70, 71). However, a study by Morioka et al. (72) indicated that cultured rat neurons expressed both cPLA2 and sPLA2 and that both PLA2s were involved in the cytokine-induced release of substance P from these neurons. Using specific antibodies, the study by Matsuzawa et al. (73) detected group IIA sPLA2 in brain synaptosomes. Furthermore, release of group IIA sPLA2 from synaptosomes was observed upon depolarization with high concentrations of potassium (73). Thus, these studies suggest the presence of sPLA2 in neurons. Studies by Kolko et al. (74–77) have provided evidence for the presence of a neuronal receptor for group IIA sPLA2. Low concentrations of sPLA2-OS2 (from Taipan snake venom) enhanced glutamate excitotoxicity, leading to neuron death (78). Injection of sPLA2 into the brain caused epileptic seizure (79) as well as neuronal apoptosis (80). Some of these effects were attributed to the ability of sPLA2 to increase Ca2+ influx through stimulation of an L-type voltage-sensitive Ca2+ channel (81).


   PLA2 IN NEUROBLASTOMA CELLS
TOP
 ABSTRACT
 INTRODUCTION
 PLA2
 PLA2 IN ASTROCYTES
 PLA2 IN MICROGLIAL CELLS
 PLA2 IN NEURONS
 PLA2 IN NEUROBLASTOMA CELLS
PLA2 IN NEURODEGENERATIVE...
 SUMMARY
 REFERENCES
 
Most tumor cells contain elevated levels of PLA2, and increased production of eicosanoids has been implicated in cell growth. Using specific PLA2 inhibitors, van Rossum et al. (82) demonstrated the involvement of cPLA2 activity in cell cycle progression, especially from G1 to S phase in neuroblastoma (N2A) cells. In human neuroblastoma LA-N-1 cells, an isoform of iPLA2 was shown to specifically utilize phosphatidylethanolamine (PE) and PE-plasmalogen as substrates (83). Differentiation of these cells with retinoic acid was marked by an increase in iPLA2 activity in the nuclei, suggesting a role for this PLA2 in regulating nuclear membrane functions (83). In another human neuroblastoma cell line, SK-N-SH, iPLA2 was involved in IL-1ß stimulation of COX-2 expression and PGE2 secretion (84) and in neuronal injury induced by hypoxia-hypoglycemia (85). Therefore, studies with neuroblastoma cells have revealed novel functions of iPLA2.


   PLA2 IN NEURODEGENERATIVE DISEASES
TOP
 ABSTRACT
 INTRODUCTION
 PLA2
 PLA2 IN ASTROCYTES
 PLA2 IN MICROGLIAL CELLS
 PLA2 IN NEURONS
 PLA2 IN NEUROBLASTOMA CELLS
 PLA2 IN NEURODEGENERATIVE...
SUMMARY
 REFERENCES
 
Information regarding the roles of different types of PLA2 in neurodegenerative diseases is sketchy, primarily because of the complex cellular network and the presence of different cell types in the brain. In this review, an attempt was made to cover studies on PLA2 in cerebral ischemia, AD, and neurodegeneration due to excitotoxic compounds. For a better coverage of PLA2 in other neurological and psychiatric disorders, including alcoholism, epilepsy, schizophrenia, and affective disorders, readers are encouraged to visit our web site (http://www.pla2.com).

Cerebral ischemia
Cessation of blood flow in cerebral ischemia (stroke) is known to trigger a number of physiological and biochemical changes, including rapid energy depletion, release of excitatory amino acid transmitters, neuronal membrane depolarization, and influx of Ca2+. Many of these changes are associated with an increase in oxidative stress, resulting in the production of ROS, which in turn, are important factors underlying delayed neuron cell death (86). In the rat focal cerebral ischemia model induced by the occlusion of the middle cerebral artery (MCA), a biphasic increase in FFAs was observed, one during the ischemic period and another at ~16 h after reperfusion (87). In the early phase of ischemia, FFA accumulation was attributed to activation of Ca2+-dependent cPLA2 as well as to an inhibition of the energy-dependent reacylation process (88). The second phase of FFA increase was attributed to upregulation of the group IIA sPLA2 in reactive astrocytes in the penumbral area (G. Y. Sun, unpublished observations). The increase in sPLA2, together with that of other lipid mediators in reactive astrocytes, is in agreement with the increased inflammatory response observed during this period of cerebral ischemia (89). In another form of MCA occlusion induced by a photochemical mechanism, an increase in group IIA sPLA2 activity was associated with ischemia-induced neuronal apoptosis (80). Indoxam, a specific sPLA2 inhibitor, was shown to offer protection against the ischemia-induced damage (80).

In the forebrain model of global cerebral ischemia, delayed neuron death was found in the hippocampal CA1 area 2 to 7 days after ischemia-reperfusion. A study by Lauritzen, Heurteaux, and Lazdunski (23) indicated a biphasic upregulation of group IIA sPLA2 mRNA in rat brain after transient global ischemia. In another study, analysis of fatty acids using different phospholipase inhibitors provided evidence that the FFA release resulting from global ischemia-reperfusion was mainly due to the activation of the Ca2+-dependent cPLA2 (90). In immature rats following hypoxic ischemia, neuron death in the CA1 hippocampal area was accompanied by an increase in COX-2 and cPLA2 immunoreactivity (91). The increase in cPLA2 immunoreactivity occurring 72 to 168 h after the ischemic insult was attributed to an increase in glial activity (91). An immunohistochemical study also indicated an increase in cPLA2 in reactive glia after global cerebral ischemia (92). Thus, neuronal damage due to ischemic injury may involve COX-2, cPLA2, and sPLA2, depending on the cell type, time course, and type of ischemic insult.

AD
Increased deposition of amyloid plaques infiltrated by reactive astrocytes and microglial cells is a major pathological landmark of AD. Aggregated forms of amyloid ß (Aß) peptides, particularly Aß1-42, have been shown to elicit cytotoxic effects resulting in neuron cell death (93, 94). Aß also stimulated astrocytes to release cytokines and nitric oxide (95), supporting the increase in oxidative and inflammatory responses in AD (93, 96, 97). Indeed, in an animal model of amyloidosis, increased lipid peroxidation was observed prior to deposition of amyloid plaques (98).

There is evidence for changes in membrane phospholipids in the AD brain. A study by Farooqui, Rapoport, and Horrocks (99) revealed a decrease in PEpl in the AD brain. In the study by Han, Holtzman, and McKee (100), a decrease in plasmenyl phospholipids was detected in the white matter of AD brain during the early stage of the disease, when only mild cognitive impairments were apparent. Plasmalogens are synthesized in peroxisomes. However, it is not clear whether the decrease in these phospholipids in the AD brain is associated with a peroxisomal disorder. Because PEpls in brain are highly enriched in DHA (2), a deficiency in these phospholipids may also lead to a decrease in DHA, which in turn, may have important implications in brain function, including learning ability (101). Recent studies in vitro demonstrated the ability of PEpl to protect cholesterol-rich membranes from oxidative stress (102). Furthermore, deficiency in PEpl could lead to altered cholesterol transport (103).

There is accumulating evidence for the involvement of specific PLA2s in AD brain pathology. In two separate studies, a decrease in PLA2 activity was found in the parietal and temporal cortex (104), as well as the prefrontal cortex, of the AD brain (105). On the other hand, immunohistochemical studies showed an increase in cPLA2 immunoreactivity associated with the glial fibrillary acidic protein-positive astrocytes in the AD brain (106). In a recent gene array study, profiling of 12,633 genes in the hippocampal CA1 area of AD patients indicated an increase in cPLA2 and COX-2 expression, as well as upregulation of a number of apoptotic and proinflammatory genes (107). These findings are in agreement with the increased oxidative and inflammatory responses and presence of reactive astrocytes associated with AD pathology (93–98).

Studies in human neuroblastoma LA-N-2 cells demonstrated the ability of Aß to enhance the activity of a number of phospholipases (108). Nicotine, a cholinergic agonist, inhibited an Aß-induced increase in PLA2 activation (109). Aß was shown to cause oxidative damage to neurons, resulting in increased Ca2+ influx and activation of apoptotic pathways (96, 97). The ability of PLA2 inhibitors to attenuate Aß-induced ROS production indicates the involvement of PLA2 in Aß cytotoxicity (110).

Neurodegeneration mediated by excitotoxic agents
Excitotoxic compounds such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-OH-dopamine have been shown to cause neurodegeneration resulting in Parkinson-like symptoms. Quinacrine, a nonselective PLA2 inhibitor, significantly reduced MPTP-induced dopamine loss (111). Mice deficient in cPLA2 were shown to exhibit more resistance to MPTP neurotoxicity than wild-type mice, further supporting a role of cPLA2 in mediating MPTP neurotoxicity (112).

Kainic acid (KA) is a subclass of glutamate receptor agonists, and systemic and/or local administration of this compound can result in seizures and neurodegeneration. Upregulation of cPLA2 expression was found in hippocampal neurons after injury induced by injection of KA into the brain (113). Quinacrine, the PLA2 inhibitor, was shown to attenuate the KA-induced increase in cPLA2 mRNA expression as well as in neuronal damage (114). Electron microscopic examination indicated two phases of upregulation of cPLA2 in the hippocampus following KA injection. The first phase was attributed to an increase in cPLA2 in the neurons, and the second phase (after 1 week) was attributed to an adaptive response associated with gliosis (114). Epileptic seizure due to KA-mediated kindling also resulted in an upregulation of COX-2 and cPLA2 in hippocampal neurons (115). These studies demonstrate a role for cPLA2 in hippocampal neuronal injury resulting from excitotoxic compounds.


   SUMMARY
TOP
 ABSTRACT
 INTRODUCTION
 PLA2
 PLA2 IN ASTROCYTES
 PLA2 IN MICROGLIAL CELLS
 PLA2 IN NEURONS
 PLA2 IN NEUROBLASTOMA CELLS
 PLA2 IN NEURODEGENERATIVE...
 SUMMARY
REFERENCES
 
A review of recent studies clearly demonstrates the important role of PLA2 in mediating normal and pathological functions in the CNS. However, studies of PLA2 in the CNS are complicated by the presence of different types of cells and the complex signaling pathways generated by different agonists (Fig. 1). Studies with astrocytes in culture reveal a link between cPLA2 and the G protein-coupled receptors and sPLA2 and the transcriptional pathways induced by proinflammatory cytokines. These studies have provided new information on mechanisms for regulating different groups of PLA2 in neural cells in the CNS.

These studies also reveal several areas requiring further studies: 1) Because iPLA2 comprises a large portion of PLA2 activity in the CNS, future studies should be directed toward a better understanding of the structure and function of different isoforms of iPLA2 in the brain. 2) Because AA release is associated with neuronal excitation, further studies are needed to clearly identify the types of PLA2 and the signaling pathways regulating AA release in neurons. 3) Studies with astrocytes may provide more information regarding the physiological roles of cPLA2 in intracellular trafficking as well as in other intracellular functions. 4) Because microglial cells have been implicated in the pathology of many neurodegenerative diseases, more studies are needed to demonstrate the role of PLA2 in the inflammatory response of these cells. With the advancement of molecular biological techniques, and as specific antibodies targeted to different PLA2s become more readily available, it can be projected that more studies will focus on defining the roles of different PLA2s in neurodegenerative diseases. It is anticipated that the new information will be important for the development of novel therapeutic strategies to combat damage resulting from upregulation of PLA2 in the affected neurodegenerative disorders.


   ACKNOWLEDGMENTS
 
Thanks are due to Dr. MaryKay Orgill for help in reading the manuscript. This research was supported in part by National Institutes of Health Grant DHHS P01 AG-18357.

Manuscript received September 21, 2003 and in revised form November 26, 2003.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 PLA2
 PLA2 IN ASTROCYTES
 PLA2 IN MICROGLIAL CELLS
 PLA2 IN NEURONS
 PLA2 IN NEUROBLASTOMA CELLS
 PLA2 IN NEURODEGENERATIVE...
 SUMMARY
 REFERENCES
 
  1. Bazan, N. G. 1970. Effects of ischemia and electroconvulsive shock on free fatty acid pool in the brain. Biochim. Biophys. Acta. 218: 1–10.[Medline]

  2. Sun, G. Y., and L. A. Horrocks. 1970. The acyl and alk-1-enyl groups of the major phosphoglycerides from ox brain myelin and mouse brain microsomal, mitochondrial and myelin fractions. Lipids. 5: 1006–1012.[CrossRef][Medline]

  3. Farooqui, A. A., L. A. Horrocks, and T. Farooqui. 2000. Deacylation and reacylation of neural membrane glycerophospholipids: a matter of life and death. J. Mol. Neurosci. 14: 123–135.[CrossRef][Medline]

  4. Lands, W. E. M., and C. G. Crawford. 1979. Enzymes of membrane phospholipid metabolism in animals. In The Enzymes of Biological Membranes. Vol. 2. A. Martonosi, editor. Plenum Press, New York. 3–85.

  5. Sun, G. Y., and R. A. MacQuarrie. 1989. Deacylation-reacylation of arachidonoyl groups in cerebral phospholipids. Ann. N.Y. Acad. Sci. 559: 37–55.[Medline]

  6. Corbin, D. R., and G. Y. Sun. 1978. Characterization of the enzymic transfer of arachidonoyl groups to 1-acyl-phosphoglycerides in mouse synaptosome fraction. J. Neurochem. 30: 77–82.[CrossRef][Medline]

  7. Cummings, B. S., J. Mchowat, and R. G. Schnellmann. 2000. Phospholipase A2s in cell injury and death. J. Pharmacol. Exp. Ther. 294: 793–799.[Abstract/Free Full Text]

  8. Murakami, M., Y. Nakatani, G. Atsumi, K. Inoue, and I. Kudo. 1997. Regulatory functions of phospholipase A2. Crit. Rev. Immunol. 17: 225–283.[Medline]

  9. Murakami, M., and I. Kudo. 2002. Phospholipase A2. J. Biochem. (Tokyo). 131: 285–292.[Abstract/Free Full Text]

  10. Fuentes, L., M. Hernandez, M. L. Nieto, and M. S. Crespo. 2002. Biological effects of group IIA secreted phospholipase A2. FEBS Lett. 531: 7–11.[CrossRef][Medline]

  11. Gijon, M. A., D. M. Spencer, and C. C. Leslie. 2000. Recent advances in the regulation of cytosolic phospholipase A2. Adv. Enzyme Reg. 40: 255–268.[CrossRef][Medline]

  12. Balboa, M. A., I. Varela-Nieto, K. K. Lucas, and E. A. Dennis. 2002. Expression and function of phospholipase A2 in brain. FEBS Lett. 531: 12–17.[CrossRef][Medline]

  13. Farooqui, A. A., H-C. Yang, T. A. Rosenberger, and L. A. Horrocks. 1997. Phospholipase A2 and its role in brain tissue. J. Neurochem. 69: 889–901.[Medline]

  14. Evans, J. H., D. M. Spencer, A. Zweifach, and C. C. Leslie. 2001. Intracellular calcium signals regulating cytosolic phospholipase A2 translocation to internal membranes. J. Biol. Chem. 276: 30151–30160.

  15. Gijon, M. A., D. M. Spencer, A. L. Kaiser, and C. C. Leslie. 1999. Role of phosphorylation sites and the C2 domain in regulation of cytosolic phospholipase A2. J. Cell Biol. 145: 1219–1232.[Abstract/Free Full Text]

  16. Fatima, S., F. A. Yaghini, A. Ahmed, Z. Khandekar, and K. U. Malik. 2003. CaM kinase II alpha mediates norepinephrine-induced translocation of cytosolic phospholipase A2 to the nuclear envelope. J. Cell Sci. 116: 353–365.[Abstract/Free Full Text]

  17. Brown, W. J., K. Chambers, and A. Doody. 2003. Phospholipase A2 (PLA2) enzymes in membrane trafficking: mediators of membrane shape and function. Traffic. 4: 214–221.[Medline]

  18. Suzuki, N., J. Ishizaki, Y. Yokota, K. Higashino, T. Ono, M. Ikeda, N. Fujii, K. Kawamoto, and K. Hanasaki. 2000. Structures, enzymatic properties, and expression of novel human and mouse secretory phospholipase A2s. J. Biol. Chem. 275: 5785–5793.[Abstract/Free Full Text]

  19. Li, W., J. Xia, and G. Y. Sun. 1999. Cytokine induction of iNOS and sPLA2 in immortalized astrocytes (DITNC): response to genistein and pyrrolidine dithiocarbamate. J. Interferon Cytokine Res. 19: 121–127.[CrossRef][Medline]

  20. Oka, S., and H. Arita. 1991. Inflammatory factors stimulate expression of group II phospholipase A2 in rat cultured astrocytes. Two distinct pathways of the gene expression. J. Biol. Chem. 266: 9956–9960.[Abstract/Free Full Text]

  21. Tong, W., Z. Y. Hu, and G. Y. Sun. 1995. Stimulation of group II phospholipase A2 mRNA expression and release in an immortalized astrocyte cell line (DITNC) by LPS, TNF{alpha}, and IL-1ß. Interactive effects. Mol. Chem. Neuropathol. 25: 1–17.[Medline]

  22. Xu, J., M. Chalimoniuk, Y. Shu, A. Simonyi, A. Y. Sun, F. A. Gonzalez, G. A. Weisman, W. G. Wood, and G. Y. Sun. 2003. Prostaglandin E2 production in astrocytes: regulation by cytokines, extracellular ATP, and oxidative agents. Prostaglandins, Leukot. Essent. Fatty Acids. 69: 437–448.[CrossRef][Medline]

  23. Lauritzen, I., C. Heurteaux, and M. Lazdunski. 1994. Expression of group II phospholipase A2 in rat brain after severe forebrain ischemia and in endotoxic shock. Brain Res. 651: 353–356.[CrossRef][Medline]

  24. Guo, Z., W. Su, Z. Ma, G. M. Smith, and M. C. Gong. 2003. Ca2+-independent phospholipase A2 is required for agonist-induced Ca2+ sensitization of contraction in vascular smooth muscle. J. Biol. Chem. 278: 1856–1863.[Abstract/Free Full Text]

  25. Atsumi, G., M. Murakami, K. Kojima, A. Hadano, M. Tajima, and I. Kudo. 2000. Distinct roles of two intracellular phospholipase A2s in fatty acid release in the cell death pathway: proteolytic fragment of type IVA cytosolic phospholipase A2{alpha} inhibits stimulus-induced arachidonate release, whereas that of group VI Ca2+-independent phospholipase A2 augments spontaneous fatty acid release. J. Biol. Chem. 275: 18248–18258.[Abstract/Free Full Text]

  26. Yang, H-C., M. Mosior, C. A. Johnson, Y. Chen, and E. A. Dennis. 1999. Group-specific assays that distinguish between the four major types of mammalian phospholipase A2. Anal. Biochem. 269: 278–288.[CrossRef][Medline]

  27. Zanassi, P., M. Paolillo, and S. Schinelli. 1998. Coexpression of phospholipase A2 in rat striatal astrocytes. Neurosci. Lett. 247: 83–86.[CrossRef][Medline]

  28. Burnstock, G. 1997. The past, present and future of purine nucleotides as signaling molecules. Neuropharmacology. 36: 1127–1139.[CrossRef][Medline]

  29. Weisman, G. A., R. C. Garrad, L. Erb, C. Santos-Berrios, and F. A. Gonzalez. 1999. P2Y receptors in the nervous system: molecular studies of a P2Y2 receptor subtype from NG-108–15 neuroblastoma x glioma hybrid cells. Prog. Brain Res. 120: 33–43.[Medline]

  30. Franke, H., U. Kruegel, R. Schmidt, J. Grosche, A. Reichenbach, and P. Illes. 2001. P2 receptor-types involved in astrogliosis in vivo. Br. J. Pharmacol. 134: 1180–1189.[CrossRef][Medline]

  31. James, G., and A. Butt. 2002. P2Y and P2X purinoceptor mediated Ca2+ signaling in glial cell pathology in the central nervous system. Eur. J. Pharmacol. 447: 247–260.[CrossRef][Medline]

  32. Neary, J. T., Y. Kang, Y. Bu, E. Yu, K. Akong, and C. M. Peters. 1999. Mitogenic signaling by ATP/P2Y purinergic receptors in astrocytes: involvement of a calcium-independent protein kinase C, extracellular signal-regulated protein kinase pathway distinct from the phosphatidylinositol-specific phospholipase C/calcium pathway. J. Neurosci. 19: 4211–4220.[Abstract/Free Full Text]

  33. Bruner, G., and S. Murphy. 1993. Purinergic P2Y receptors on astrocytes are directly coupled to phospholipase A2. Glia. 7: 219–224.[CrossRef][Medline]

  34. Chen, W. C., and C. C. Chen. 1998. ATP-induced arachidonic acid release in cultured astrocytes is mediated by Gi-protein-coupled P2Y1 and P2Y2 receptors. Glia. 22: 360–370.[CrossRef][Medline]

  35. Stella, N., A. Estelles, J. Siciliano, M. Tence, S. Desagher, D. Piomelli, J. Glowinski, and J. Premont. 1997. Interleukin-1 enhances the ATP-evoked release of arachidonic acid from mouse astrocytes. J. Neurosci. 17: 2939–2946.[Abstract/Free Full Text]

  36. Xu, J., Y. I. Weng, A. Simonyi, B. W. Krugh, J. Liao, G. A. Weisman, and G. Y. Sun. 2002. Role of PKC and MAPK in cytosolic PLA2 phosphorylation and arachidonic acid release in primary murine astrocytes. J. Neurochem. 83: 259–270.[CrossRef][Medline]

  37. Strokin, M., M. Sergeeva, and G. Reiser. 2003. Docosahexaenoic acid and arachidonic acid release in rat brain astrocytes is mediated by two separate isoforms of phospholipase A2 and is differently regulated by cyclic AMP and Ca2+. Br. J. Pharmacol. 139: 1014–1022.[CrossRef][Medline]

  38. Tence, M., J. Cordier, J. Glowinski, and J. Premont. 1992. Endothelin-evoked release of arachidonic acid from mouse astrocytes in primary culture. Eur. J. Neurosci. 4: 993–999.[CrossRef][Medline]

  39. Abdel-Latif, A. A., S. Husain, and S. Y. K. Yousufzai. 2000. Role of protein kinase C alpha and mitogen-activated protein kinases in endothelin-1-stimulation of cytosolic phospholipase A2 in iris sphincter smooth muscle. J. Cardiovasc. Pharmacol. 36 (Suppl.): 117–119.

  40. Trevisi, L., S. Bova, G. Cargnelli, G. Ceolotto, and S. Luciani. 2002. Endothelin-1-induced arachidonic acid release by cytosolic phospholipase A2 activation in rat vascular smooth muscle via extracellular signal-regulated kinases pathway. Biochem. Pharmacol. 64: 425–431.[CrossRef][Medline]

  41. Kurrasch-Orbaugh, D. M., V. J. Watts, E. L. Barker, and D. E. Nichols. 2003. Serotonin 5-hydroxytryptamine (2A) receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. J. Pharmacol. Exp. Ther. 304: 229–237.[Abstract/Free Full Text]

  42. Kurrasch-Orbaugh, D. M., J. C. Parrish, V. J. Watts, and D. E. Nichols. 2003. A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases. J. Neurochem. 86: 980–991.[CrossRef][Medline]

  43. Robb, S. J., L. D. Robb-Gaspers, R. C. Scaduto, Jr., A. P. Thomas, and J. R. Connor. 1999. Influence of calcium and iron on cell death and mitochondrial function in oxidatively stressed astrocytes. J. Neurosci. Res. 55: 674–685.[CrossRef][Medline]

  44. Rohrdanz, E., and E. Kahl. 1998. Alterations of antioxidant enzyme expression in response to hydrogen peroxide. Free Radic. Biol. Med. 24: 27–38.[CrossRef][Medline]

  45. Suzuki, Y. J., H. J. Forman, and A. Sevanian. 1997. Oxidants as stimulators of signal transduction. Free Radic. Biol. Med. 22: 269–285.[CrossRef][Medline]

  46. Gopalakrishna, R., and S. Jaken. 2000. Protein kinase C signaling and oxidative stress. Free Radic. Biol. Med. 28: 1349–1361.[CrossRef][Medline]

  47. Konishi, H., M. Tanaka, Y. Takemura, H. Matsuzaki, Y. Ono, Y. Kikkawa, and Y. Nishizuka. 2001. Activation of protein kinase C by tyrosine phosphorylation in response to H2O2. Proc. Natl. Acad. Sci. USA. 94: 11233–11237.

  48. Rosenberger, J., G. Petrovics, and B. Buzas. 2001. Oxidative stress induces proorphanin FQ and proenkephalin gene expression in astrocytes through p38- and ERK-MAP kinases and NF-{kappa}B. J. Neurochem. 79: 35–44.[CrossRef][Medline]

  49. Servitja, J. M., R. Masgrau, R. Pardo, E. Srri, and F. Picatoste. 2000. Effects of oxidative stress on phospholipid signaling in rat cultured astrocytes and brain slices. J. Neurochem. 75: 788–794.[CrossRef][Medline]

  50. Tournier, K., G. Thomas, J. Pierre, C. Jacquemin, M. Pierre, and B. Saunier. 1997. Mediation by arachidonic acid metabolites of the H2O2-induced stimulation of mitogen-activated protein kinases (extracellular-signal-regulated kinase and c-Jun NH2-terminal kinase). Eur. J. Biochem. 244: 587–595.[Medline]

  51. Xu, J., S. Yu, A. Y. Sun, and G. Y. Sun. 2003. Oxidant-mediated AA release from astrocytes involves cPLA2 and iPLA2. Free Radic. Biol. Med. 34: 1531–1543.[CrossRef][Medline]

  52. Han, W. K., A. Sapirstein, C. C. Hung, A. Alessandrini, and J. V. Bonventre. 2003. Cross-talk between cytosolic phospholipase A2alpha (cPLA2alpha) and secretory phospholipase A2 (sPLA2) in hydrogen peroxide-induced arachidonic acid release in murine mesangial cells. SPLA2 regulates cPLA2alpha activity that is responsible for arachidonic acid release. J. Biol. Chem. 278: 24153–24163.[Abstract/Free Full Text]

  53. Kennedy, B. P., P. Payette, J. Mudgett, P. Vadas, W. Pruzanski, M. Kwan, C. Tang, D. E. Rancourt, and W. A. Cromlish. 1995. A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. J. Biol. Chem. 270: 22378–22385.[Abstract/Free Full Text]

  54. Ghosh, M., A. Stewart, D. E. Tucker, J. V. Bonventre, R. C. Murphy, and C. C. Leslie. 2004. Role of cytosolic phospholipase A2 in prostaglandin E2 production by lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 30:91–100.[Abstract/Free Full Text]

  55. Pardue, S., S. I. Rapoport, and F. Bosetti. 2003. Co-localization of cytosolic phosplolipase A(2) and cyclooxygenase-2 in Rhesus monkey cerebellum. Brain Res. Mol. Brain Res. 116: 106–114.[Medline]

  56. Hernandez, M., Y. Bayon, C. M. Sanchez, and M. L. Nieto. 1999. Signaling mechanisms involved in the activation of arachidonic acid metabolism in human astrocytoma cells by tumor necrosis factor alpha: phosphorylation of cytosolic phospholipase A2 and transactivation of cyclooxygenase-2. J. Neurochem. 73: 1641–1649.[CrossRef][Medline]

  57. Thomas, G., F. Bertrand, and B. Saunier. 2000. The differential regulation of group IIA and group V low molecular weight phospholipase A2 in cultured rat astrocytes. J. Biol. Chem. 275: 10876–10886.[Abstract/Free Full Text]

  58. Aloisi, F. 2001. Immune function of microglia. Glia. 36: 165–179.[CrossRef][Medline]

  59. Paris, D., T. Town, and M. Mullan. 2000. Novel strategies for opposing murine microglial activation. Neurosci. Lett. 278: 5–8.[CrossRef][Medline]

  60. Hoozemans, J. J. M., R. Veerhuis, I. Janssen, E. J. van Elk, A. J. M. Rozemuller, and P. Eikelenboom. 2002. The role of cyclo-oxygenase 1 and 2 activity in prostaglandin E2 secretion by cultured human adult microglia: implications for Alzheimer's disease. Brain Res. 951: 218–226.[CrossRef][Medline]

  61. Massicotte, G. 2000. Modification of glutamate receptors by phospholipase A2: its role in adaptive neural plasticity. Cell. Mol. Life Sci. 57: 1542–1550.[CrossRef][Medline]

  62. Taylor, A. L., and S. J. Hewitt. 2002. Potassium-evoked glutamate release liberates arachidonic acid from cortical neurons. J. Biol. Chem. 15: 43881–43887.

  63. Williams, R. J., and J. Glowinski. 1996. Cyclothiazide unmasks an AMPA-evoked release of arachidonic acid from cultured striatal neurons. J. Neurochem. 67: 1551–1558.[Medline]

  64. Navamani, M., M. Morgan, and R. Williams. 1997. Ethanol modulates N-methyl-D-aspartate-evoked arachidonic acid release from neurons. Eur. J. Pharmacol. 340: 27–34.[CrossRef][Medline]

  65. Marin, P., B. Hamon, J. Glowinski, and J. Premont. 1997. Nicotine-induced inhibition of neuronal phospholipase A2. J. Pharmacol. Exp. Ther. 280: 1277–1283.[Abstract/Free Full Text]

  66. Tence, M., J. Cordier, J. Premont, and J. Glowinski. 1994. Muscarinic cholinergic agonists stimulate arachidonic acid release from mouse striatal neurons in primary culture. J. Pharmacol. Exp. Ther. 269: 646–653.[Abstract/Free Full Text]

  67. Samanta, S., M. S. Perkinton, M. Morgan, and R. J. Williams. 1998. Hydrogen peroxide enhances signal-responsive arachidonic acid release from neurons: role of mitogen-activated protein kinase. J. Neurochem. 70: 2082–2090.[Medline]

  68. Kishimoto, K., K. Matsumura, Y. Kataoka, H. Morii, and Y. Watanabe. 1999. Localization of cytosolic phospholipase A2 messenger RNA mainly in neurons in the rat brain. Neuroscience. 92: 1061–1077.[CrossRef][Medline]

  69. Pepicelli, O., E. Fedele, G. Bonanno, M. Raiteri, M. A. Ajmone-Cat, A. Greco, G. Levi, and L. Minghetti. 2002. In vivo activation of N-methyl-D-aspartate receptors in the rat hippocampus increases prostaglandin E2 extracellular levels and triggers lipid peroxidation through cyclooxygenase-mediated mechanisms. J. Neurochem. 81: 1028–1034.[CrossRef][Medline]

  70. Hornfelt, M., P. A. R. Ekstrom, and A. Edstrom. 1999. Involvement of axonal phospholipase A2 activity in the outgrowth of adult mouse sensory axons in vitro. Neuroscience. 91: 1539–1547.[CrossRef][Medline]

  71. Hornfelt, M., A. Edstrom, and P. A. R. Ekstrom. 1999. Upregulation of cytosolic phospholipase A2 correlates with apoptosis in mouse cervical and dorsal root ganglia neurons. Neurosci. Lett. 265: 87–90.[CrossRef][Medline]

  72. Morioka, N., K. Takeda, K. Kumagai, T. Hanada, K. Ikoma, I. Hide, A. Inoue, and Y. Nakata. 2002. Interleukin-1 beta-induced substance P release from rat cultured primary afferent neurons driven by two phospholipase A2 enzymes: secretory type IIA and cytosolic type IV. J. Neurochem. 80: 989–997.[CrossRef][Medline]

  73. Matsuzawa, A., M. Murakami, G. Atsumi, K. Imai, P. Prados, K. Inue, and I. Kudo. 1996. Release of secretory phospholipase A2 from rat neuronal cells and its possible function in the regulation of catecholamine secretion. Biochem. J. 318: 701–709.

  74. Kolko, M., M. A. Decoster, E. B. R. Deturco, and N. G. Bazan. 1996. Synergy by secretory phospholipase A2 and glutamate on inducing cell death and sustained arachidonic acid metabolic changes in primary cortical neuronal cultures. J. Biol. Chem. 271: 32722–32728.[Abstract/Free Full Text]

  75. Kolko, M., T. Bruhn, T. Christensen, M. Lazdunski, G. Lambeau, N. G. Bazan, and N. H. Diemer. 1999. Secretory phospholipase A2 potentiates glutamate-induced rat striatal neuronal cell death in vivo. Neurosci. Lett. 274: 167–170.[CrossRef][Medline]

  76. Kolko, M., M. Nielsen, N. G. Bazan, and N. H. Diemer. 2002. Secretory phospholipase A2 induces delayed neuronal COX-2 expression compared with glutamate. J. Neurosci. Res. 69: 169–177.[CrossRef][Medline]

  77. Kolko, M., E. B. R. de Turco, N. H. Diemer, and N. G. Brazan. 2002. Secretory phospholipase A2-mediated neuronal cell death involves glutamate ionotropic receptors. Neuroreport. 13: 1963–1966.[CrossRef][Medline]

  78. De Turco, E. B. R., F. R. Jackson, M. A. DeCoster, M. Kolko, and N. G. Bazan. 2002. Glutamate signaling and secretory phospholipase A2 modulate the release of arachidonic acid from neuronal membranes. J. Neurosci. Res. 68: 558–567.[CrossRef][Medline]

  79. Dorandeu, F., I. Pernotmarino, J. Veyret, C. Perrichon, and G. Lallement. 1998. Secreted phospholipase A2-induced neurotoxicity and epileptic seizures after intracerebral administration: an unexplained heterogeneity as emphasized with paradoxin and crotoxin. J. Neurosci. Res. 54: 848–862.[CrossRef][Medline]

  80. Yagami, T., K. Ueda, K. Asakura, S. Hata, T. Kuroda, T. Sakaeda, N. Takasu, K. Tanaka, T. Gemba, and Y. Hori. 2002. Human group IIA secretory phospholipase A2 induces neuronal cell death via apoptosis. Mol. Pharmacol. 61: 114–126.[Abstract/Free Full Text]

  81. Yagami, T., K. Ueda, K. Asakura, H. Nakazato, S. Hata, T. Kuroda, T. Sakaeda, G. Sakaguchi, N. Itoh, Y. Hashimoto, and Y. Hori. 2003. Human group IIA secretory phospholipase A2 potentiates Ca2+ influx through L-type voltage-sensitive Ca2+ channels in cultured rat cortical neurons. J. Neurochem. 85: 749–758.[CrossRef][Medline]

  82. Van Rossum, G. S. A. T., J. J. M. Bijvelt, H. van den Bosch, A. J. Verkleij, and J. Boonstra. 2002. Cytosolic phospholipase A2 and lipoxygenase are involved in cell cycle progression in neuroblastoma cells. Cell. Mol. Life Sci. 59: 181–188.[CrossRef][Medline]

  83. Antony, P., L. Freysz, L. A. Horrocks, and A. A. Farooqui. 2001. Effect of retinoic acid on the Ca2+-independent phospholipase A2 in nuclei of LA-N-1 neuroblastoma cells. Neurochem. Res. 26: 83–88.[CrossRef][Medline]

  84. Hoozemans, J. J. M., R. Veerhuis, I. Janssen, A. J. Rozemuller, and P. Eikelenboom. 2001. Interleukin-1beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer's disease. Exp. Gerontol. 36: 559–570.[CrossRef][Medline]

  85. Petroni, A., N. Papini, M. Blasevich, P. Rise, and C. Galli. 2002. Arachidonate release and c-fos expression in various models of hypoxia and hypoxia-hypoglycemia in retinoic acid differentiated neuroblastoma cells. Neurochem. Int. 40: 255–260.[CrossRef][Medline